ArticleCancer immunology, immunotherapy : CII2021
Serum levels of the IL-6 family of cytokines predict prognosis in renal cell carcinoma (RCC).
Article in Cancer immunology, immunotherapy : CII, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 36 citations in OpenAlex.
- A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma.Cancer discovery · 2022Trial
- A prediction model for targeted drug resistance in renal cell carcinoma based on plasma proteomics analysis.Translational andrology and urology · 2026Article
- PIM1 expression is prognostic in clear cell renal cell carcinoma and influenced by an IL-6/JAK/STAT axis.American journal of cancer research · 2026Article
- Urine C-reactive protein content and non-invasive molecular grading of renal cell carcinoma.Kidney cancer journal : official journal of the Kidney Cancer Association · 2025Article
- A novel programmed cell death signature predicts clinical outcomes in clear cell renal cell carcinoma and identifies PLK1 as a therapeutic target.Apoptosis : an international journal on programmed cell death · 2025Article
- Advances in research on malignant tumors and targeted agents for TOP2A (Review).Molecular medicine reports · 2025Review
- Immune analysis of urine and plasma samples from patients with clear cell renal cell carcinoma.Oncology letters · 2024Article
- Article
- Mathematical and Machine Learning Models of Renal Cell Carcinoma: A Review.Bioengineering (Basel, Switzerland) · 2023Review
- An observational study of the impact of immediate breast reconstruction on perioperative inflammatory cytokines.Surgery today · 2023Observational
- Inflammatory Networks in Renal Cell Carcinoma.Cancers · 2023Review
- Liquid biopsy at the frontier in renal cell carcinoma: recent analysis of techniques and clinical application.Molecular cancer · 2023Review
- Circulating cytokines allow for identification of malignant intraductal papillary mucinous neoplasms of the pancreas.Cancer medicine · 2023Article
- Molecules promoting circulating clusters of cancer cells suggest novel therapeutic targets for treatment of metastatic cancers.Frontiers in immunology · 2023Review
- Article
- Patient-Specific Mathematical Model of the Clear Cell Renal Cell Carcinoma Microenvironment.Journal of personalized medicine · 2022Article
- Article
- Complexity in radiological morphology predicts worse prognosis and is associated with an increase in proteasome component levels in clear cell renal cell carcinoma.Frontiers in oncology · 2022Article
- A Bioinformatic Analysis of Immune-Related Prognostic Genes in Clear Cell Renal Cell Carcinoma Based on TCGA and GEO Databases.International journal of general medicine · 2022Article
- Nitric Oxide-Releasing Drug Glyceryl Trinitrate Targets JAK2/STAT3 Signaling, Migration and Invasion of Triple-Negative Breast Cancer Cells.International journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAn improved understanding of RCC immunology should shed further light on RCC tumor biology. Our objective was to study to what extent serum levels of the IL-6 family of cytokines at diagnosis were relevant to survival.
methodsA total of 118 consecutively patients with RCC, in which the tumor was surgically removed at Haukeland University Hospital during the period from 2007 to 2010, were included. The patients were followed-up for 10 years. The morning before surgery blood was sampled and serum frozen, with levels of IL-6, IL-27, IL-31, OSM, CNTF, IL-6Rα and gp130 determined.
resultsAmong patients with the highest quartile of IL-6 (> 8 pg/ml) (n = 29), six of nine who had metastasis at diagnosis had such high IL-6 values. Among presumed radically treated patients, a high IL-6 and IL-27 strongly predicted recurrence. In particular, the predictions among patients with large (diameter > 7 cm) tumors were excellent regarding both IL-6 and IL-27 values. High gp130 serum levels predicted an overall survival (OS) among RCC patients with large tumors. Patients with a high IL-6 exhibited a strong expression of IL-6 in endothelial- and vascular smooth muscle cells. Moreover, the level of intra-tumoral CD3-positive cells predicted survival.
conclusionsIL-6 and IL-27 seem to play a role in RCC biology. IL-6 enables the pinpointing of metastatic condition at diagnosis, as well as together with IL-27, the predicting of survival and recurrence. Endothelial cells and vascular smooth muscle cells are both suggested as important sources of IL-6.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.